Pinkerton Retirement Specialists LLC Acquires 1,672 Shares of GlaxoSmithKline plc (NYSE:GSK)

Pinkerton Retirement Specialists LLC increased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 3.1% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 55,944 shares of the pharmaceutical company’s stock after purchasing an additional 1,672 shares during the period. Pinkerton Retirement Specialists LLC’s holdings in GlaxoSmithKline were worth $2,239,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of GSK. Comerica Securities Inc. raised its holdings in shares of GlaxoSmithKline by 2.6% during the 4th quarter. Comerica Securities Inc. now owns 12,984 shares of the pharmaceutical company’s stock valued at $502,000 after buying an additional 326 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of GlaxoSmithKline by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,769,859 shares of the pharmaceutical company’s stock valued at $67,626,000 after buying an additional 88,148 shares during the period. Norges Bank purchased a new stake in shares of GlaxoSmithKline during the 4th quarter valued at about $17,275,000. Geode Capital Management LLC raised its holdings in shares of GlaxoSmithKline by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 424,397 shares of the pharmaceutical company’s stock valued at $16,216,000 after buying an additional 48,476 shares during the period. Finally, CWM LLC raised its holdings in shares of GlaxoSmithKline by 28.4% during the 1st quarter. CWM LLC now owns 3,655 shares of the pharmaceutical company’s stock valued at $153,000 after buying an additional 808 shares during the period. Institutional investors and hedge funds own 11.30% of the company’s stock.

GSK has been the topic of several analyst reports. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. Morgan Stanley restated an “underweight” rating on shares of GlaxoSmithKline in a research note on Monday, June 17th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Finally, Cowen restated a “hold” rating and set a $45.00 price objective on shares of GlaxoSmithKline in a research note on Monday, June 10th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $41.79.



NYSE GSK traded up $0.47 during mid-day trading on Friday, reaching $41.45. 1,382,191 shares of the company’s stock traded hands, compared to its average volume of 2,410,493. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $42.47. The company has a fifty day simple moving average of $40.89 and a 200-day simple moving average of $40.49. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86. The company has a market cap of $101.65 billion, a price-to-earnings ratio of 13.12, a P/E/G ratio of 1.96 and a beta of 0.71.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The firm had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. Equities research analysts forecast that GlaxoSmithKline plc will post 2.91 earnings per share for the current fiscal year.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 333,333 shares of the stock in a transaction on Monday, July 1st. The stock was purchased at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. 10.00% of the stock is owned by company insiders.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Percentage Decliners

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.